RE:RE:RE:Anyone know what our "Cash Position" is at "real time"?Thank you for the information I am happy to hear that they have enough funds to last through 2022 obviously that puts more emphasis on the trial data needing to be stellar. Hopefully management is already in parallel talks with big Pharma now for Joint Venture deals I wish they were sitting on a little more cash as it is always better to be negotiating from a position of financial strength rather than be in a position where they have to rush a deal to keep the lights on. Ideally we get JV cash or a good buyout but I would not rule out another dilution raise completely I would peg the odds of that at 50/50 right now if I am being realistic